Skip to content

Savara SVRA Short-Term Investments

Short-Term Investments at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$105.02M+315%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$106.57M+426%
TRV
Trevi Therapeutics, Inc.TRVI
$152.37M+81.6%
United Therapeutics logo
United TherapeuticsUTHR
$874M-38.5%
Insmed logo
InsmedINSM
$641.33M-19.5%
Mannkind logo
MannkindMNKD
$81.03M-39.6%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.24B+247%
Enterprise value$1.23B+235%
P/S4,808.2×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's short-term investments?
Savara (SVRA) reported short-term investments of $163.98M in Q1 2026.
How has Savara's short-term investments changed year-over-year?
Savara's short-term investments increased by 7.2% year-over-year, from $152.94M to $163.98M.
What is the long-term trend for Savara's short-term investments?
Over 5 years (2020 to 2025), Savara's short-term investments has grown at a 27.8% compound annual growth rate (CAGR), from $59.31M to $202.52M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.